



647

Please type a plus sign (+) inside this box ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/898,751	
	Filing Date	July 2, 2001	
	First Named Inventor	Wei Wang, et al.	
	Group Art Unit	1647	
	Examiner Name	Bunner, Bridget E.	
Total Number of Pages in This Submission	9	Attorney Docket Number	DX0882XK

TECH CENTER 1600/2400

SEP 25 2001

RECEIVED

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment (Response) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below) Certificate of Mailing - 1 pg. Return Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Sandy Zaradic, Reg. No. 45,997
Signature	
Date	September 16, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: September 16, 2002	
Typed or printed name	Sandy Zaradic, Reg. No. 45,997
Signature	
Date	September 16, 2002

+

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Attorney Docket No.: DX0882XK

Serial No.: 09/898,751

Filing Date: July 2, 2002

Inventor: Wei Wang, et al.

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**Assistant Commissioner for Patents
Washington, D.C. 20231**

on September 16, 2002

Date

Signature

Sandy Zaradic, Reg. No. 45,997

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:


Response to Restriction Requirement - 7 pages

Response Transmittal - 1 page

Certificate of Mailing - 1 page

Return Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



#111
6/26/02

PATENT CASE: DX0882XK

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wei Wang *et al.*

Examiner: Bunner, Bridget E.

For:
Chemokine and Receptor Uses;
Compositions; Methods

Group Art Unit: 1647

Serial No.: 09/898,751

Filing Date: July 2, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is in response to the Office Action, Paper No. 10, (Confirmation No. 7429) mailed August 16, 2002, for which a response is due September 16, 2002. Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0365.

PLEASE AMEND THE APPLICATION AS FOLLOWS:

IN THE CLAIMS

Cancel claims 5-21.

Amend claims 1-4 and 22-23 as follows:

- A1 sub 857
1. A method of modulating movement of a cell within or to the skin of a mammal, said method comprising administering to said mammal an effective amount of an antagonist of CTACK.
 2. The method of Claim 1, wherein said modulating is blocking and said administering is an antagonist of CTACK.
 3. The method of Claim 2, wherein:
 - a) said movement is within said skin;
 - b) said administering is local, systemic, topical, subcutaneous, intradermal, or transdermal;
 - c) said administering is an antagonist of CTACK;
 - d) said cell is a CLA+ cell; or
 - e) said cell moves into the dermis and/or epidermis layers of said skin.
 4. The method of Claim 2, wherein:
 - a) said antagonist is an antibody which neutralizes CTACK;
 - b) said mammal is subject to a transplant or skin graft;
 - c) said antagonist is administered in combination with an antibiotic.

A2 sub 857

22. A method of treating a patient suffering from a skin disorder comprising administering an effective amount of an antagonist against CTACK.

23. The method of Claim 22, wherein the antagonist is an antibody.